Amid Miplyffa launch, Zevra CEO aims to foster EU-style Niemann-Pick market in US

As its ultra-rare disease med Miplyffa strengthens its foothold in the U.S., Zevra Therapeutics’ CEO believes the launch has the potential to convert the American treatment landscape for Niemann-Pi | As its ultra-rare disease med Miplyffa strengthens its foothold in the U.S., Zevra Therapeutics’ CEO believes the launch has the potential to convert the American treatment landscape for Niemann-Pick disease type C into one resembling Europe’s.